Quick Takeaways
- UBS Group AG filed SCHEDULE 13G/A for Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX).
- Disclosed ownership: 0%.
- Date of event: 31 Dec 2024.
UBS Group AG - 31 Dec 2024 SCHEDULE 13G/A Report for Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX)
- Filing Manager
- UBS Group AG
- Reporting Manager
- UBS Group AG
- Symbol
- AMRX
- Disclosed Ownership
- 0 shares
- Ownership
- 0%
- Form type
- SCHEDULE 13G/A
- Filing time
- 10 Feb 2025, 08:59:12 UTC
- Date of event
- 31 Dec 2024
- Previous filing
- 30 Oct 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"UBS Group AG disclosed 0% ownership in Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX) on 31 Dec 2024."
What Changed
- Previous schedule filing date: 30 Oct 2024.
- Current filing was accepted on 10 Feb 2025, 08:59.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| UBS Group AG | 0% | 0 | 0 | 0 | Andrew Johnson | Director |